Madhukiran Parvathaneni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Madhukiran Parvathaneni has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Ganga Rao Battu
Andhra University
3 shared publications- Veera Venkata Satyanarayana Reddy Karri
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, Nilgiris, Tamil Nadu, India
3 shared publications - Divya Pamu
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643001, India
2 shared publications - Lavanya Mude
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643001, India
2 shared publications - Sai Varshini Magham
Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643001, India
2 shared publications - Vasanth Raj Palanimuthu
Department of Pharmaceutical Biotechnology, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Ooty 643001, India
2 shared publications
Latest Publications
- Open Access
- 17 March 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 161, 114540
Human beta defensin-2 loaded PLGA nanoparticles impregnated in collagen-chitosan composite scaffold for the management of diabetic wounds
- 17 March 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 161, 114540
Open AccessHuman beta defensin-2 loaded PLGA nanoparticles impregnated in collagen-chitosan composite scaffold for the management of diabetic wounds
- Open Access
- 15 January 2023
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 13 (1) , 151-158
Application of Artificial Intelligence and Machine Learning in Drug Discovery and Development
Drug discovery has traditionally been a time consuming and expensive endeavor. Additionally, drugs weren’t as effectively designed as those that are being predicted and developed through AI and ML today. Machine learning is a form of artificial intelligence that develops and evolves based on experience (similarly to the human mind), and is more recently being utilized in drug discovery and design. The integration of AI and ML into the drug discovery and development process has allowed for higher target precision, lower toxicity, and better dosage formulations. AI more generally has been introduced to and has been leveraged at, each step of drug development, including target identification and validation, hit identification, as well as hit to lead optimization, and has been key in shortening the previously lengthy drug screening process. AI and ML has also been applied downstream in drug formulation where it has maximized resource utilization and is allowing for web-based 3D printing of drugs. Application of AI in the drug development process has also been extended to the modeling of novel drug-like compounds to predict their ADMET properties. This review will address the stages of drug discovery and development in which the application of AI and ML modeling has altered the traditional development of drugs. Keywords: Drug discovery, machine learning, artificial intelligence, computational drug development.
- 15 January 2023
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 13 (1) , 151-158
Open AccessApplication of Artificial Intelligence and Machine Learning in Drug Discovery and Development
Drug discovery has traditionally been a time consuming and expensive endeavor. Additionally, drugs weren’t as effectively designed as those that are being predicted and developed through AI and ML today. Machine learning is a form of artificial intelligence that develops and evolves based on experience (similarly to the human mind), and is more recently being utilized in drug discovery and design. The integration of AI and ML into the drug discovery and development process has allowed for higher target precision, lower toxicity, and better dosage formulations. AI more generally has been introduced to and has been leveraged at, each step of drug development, including target identification and validation, hit identification, as well as hit to lead optimization, and has been key in shortening the previously lengthy drug screening process. AI and ML has also been applied downstream in drug formulation where it has maximized resource utilization and is allowing for web-based 3D printing of drugs. Application of AI in the drug development process has also been extended to the modeling of novel drug-like compounds to predict their ADMET properties. This review will address the stages of drug discovery and development in which the application of AI and ML modeling has altered the traditional development of drugs. Keywords: Drug discovery, machine learning, artificial intelligence, computational drug development.
- Open Access
- 15 January 2023
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 13 (1) , 159-164
A Review on Strategies for COVID-19 Vaccine Development and Regulatory Requirements
Scientists first identified Human Coronavirus in the year 1965. Then, a study was performed on different human and animal viruses, which were named based on their crown-like appearance. Human coronaviruses are responsible for many children's upper respiratory tract infections. At least five new human coronaviruses have been identified since 2003, including the severe acute respiratory syndrome (SARS) coronavirus, which caused significant morbidity and mortality.1 Per NL and the New Haven, the virus associated with upper and lower respiratory tract disease and likely common human pathogens are identified as the Group-I coronaviruses (SARS- CoV-I). The novel coronavirus (SARS-CoV-II), which appeared in Wuhan, China, in December 2019, is responsible for Coronavirus disease 2019 (COVID-19) and causes respiratory symptoms that can feel like a cold, flu, or pneumonia. Geographical transmission of the virus and the sudden increase in cases are much faster than SARS and Middle East respiratory syndrome (MERS). COVID-19 is the first global pandemic caused by a coronavirus causing outbreaks in 211 countries. The vaccine against COVID-19 is an effective prophylactic strategy for controlling and preventing the virus. The vaccine is being developed in about 90 institutions worldwide. This research paper focuses on COVID-19 vaccine development strategies implemented by various institutions and pharmaceutical companies worldwide and regulatory requirements for vaccine approval. Keywords: Human Coronavirus, Severe Acute Respiratory Syndrome (SARS), COVID-19 vaccine development strategies
- 15 January 2023
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 13 (1) , 159-164
Open AccessA Review on Strategies for COVID-19 Vaccine Development and Regulatory Requirements
Scientists first identified Human Coronavirus in the year 1965. Then, a study was performed on different human and animal viruses, which were named based on their crown-like appearance. Human coronaviruses are responsible for many children's upper respiratory tract infections. At least five new human coronaviruses have been identified since 2003, including the severe acute respiratory syndrome (SARS) coronavirus, which caused significant morbidity and mortality.1 Per NL and the New Haven, the virus associated with upper and lower respiratory tract disease and likely common human pathogens are identified as the Group-I coronaviruses (SARS- CoV-I). The novel coronavirus (SARS-CoV-II), which appeared in Wuhan, China, in December 2019, is responsible for Coronavirus disease 2019 (COVID-19) and causes respiratory symptoms that can feel like a cold, flu, or pneumonia. Geographical transmission of the virus and the sudden increase in cases are much faster than SARS and Middle East respiratory syndrome (MERS). COVID-19 is the first global pandemic caused by a coronavirus causing outbreaks in 211 countries. The vaccine against COVID-19 is an effective prophylactic strategy for controlling and preventing the virus. The vaccine is being developed in about 90 institutions worldwide. This research paper focuses on COVID-19 vaccine development strategies implemented by various institutions and pharmaceutical companies worldwide and regulatory requirements for vaccine approval. Keywords: Human Coronavirus, Severe Acute Respiratory Syndrome (SARS), COVID-19 vaccine development strategies
- Open Access
Growth Factor Loaded Thermo-Responsive Injectable Hydrogel for Enhancing Diabetic Wound Healing
Background: Diabetic wound (DW) is the most devastating complication resulting in significant mortality and morbidity in diabetic patients. The objective of the current study was to formulate Epidermal Growth Factor loaded Chitosan nanoparticle impregnated with thermos-responsive injectable hydrogel with protease inhibitor. EGF, shown in all stages of wound healing from inflammation to proliferation and remodelling, combined with Doxycycline, a well-known anti-inflammatory and anti-bacterial drug, could be a better strategy in diabetic wound healing. However, EGF’s low stability makes it difficult to use. Methodology: The nanoparticles were prepared using the ionic gelation method. The prepared nanoparticles were evaluated for particle size, zeta potential, entrapment efficiency, and SEM studies. Further, the optimized nanoparticle batch was loaded into hydrogel with a protease inhibitor. The hydrogel was evaluated for morphology, protease degradation, in vitro drug release, anti-bacterial activity, cell migration, in vitro cell biocompatibility, and in vivo wound healing studies. Results and Conclusion: The particle size analysis of nanoparticles revealed the size (203 ± 1.236 nm), Zeta potential (+28.5 ± 1.0 mV), and entrapment efficiency of 83.430 ± 1.8%, respectively. The hydrogel showed good porous morphology, injectability, thermo-responsive, biocompatibility, and controlled drug release. In vitro anti-bacterial studies revealed the potential anti-bacterial activity of doxycycline against various microbes. In vivo data indicated that combining EGF and DOX considerably reduced inflammation time-dependent than single-agent treatment. Furthermore, histological studies corroborated these findings. After topical application of hydrogel, histopathology studies revealed significant collagen synthesis and a fully regenerated epithelial layer and advancement in all three stages (proliferation, remodelling, and maturation), which are required to improve the diabetic wound healing process by any dressing. These findings demonstrated that hydrogel promoted cutaneous wound healing in STZ-induced rats by suppressing inflammation at the wound site. Furthermore, histological studies corroborated these findings. After topical application of hydrogel, histopathology studies revealed significant collagen synthesis, a fully regenerated epithelial layer, and advancement in all three stages (proliferation, remodelling, and maturation), which are required to improve the diabetic wound healing process by any dressing. These findings demonstrated that hydrogel promoted cutaneous wound healing in STZ-induced rats by suppressing inflammation at the wound site.
Open AccessGrowth Factor Loaded Thermo-Responsive Injectable Hydrogel for Enhancing Diabetic Wound Healing
Background: Diabetic wound (DW) is the most devastating complication resulting in significant mortality and morbidity in diabetic patients. The objective of the current study was to formulate Epidermal Growth Factor loaded Chitosan nanoparticle impregnated with thermos-responsive injectable hydrogel with protease inhibitor. EGF, shown in all stages of wound healing from inflammation to proliferation and remodelling, combined with Doxycycline, a well-known anti-inflammatory and anti-bacterial drug, could be a better strategy in diabetic wound healing. However, EGF’s low stability makes it difficult to use. Methodology: The nanoparticles were prepared using the ionic gelation method. The prepared nanoparticles were evaluated for particle size, zeta potential, entrapment efficiency, and SEM studies. Further, the optimized nanoparticle batch was loaded into hydrogel with a protease inhibitor. The hydrogel was evaluated for morphology, protease degradation, in vitro drug release, anti-bacterial activity, cell migration, in vitro cell biocompatibility, and in vivo wound healing studies. Results and Conclusion: The particle size analysis of nanoparticles revealed the size (203 ± 1.236 nm), Zeta potential (+28.5 ± 1.0 mV), and entrapment efficiency of 83.430 ± 1.8%, respectively. The hydrogel showed good porous morphology, injectability, thermo-responsive, biocompatibility, and controlled drug release. In vitro anti-bacterial studies revealed the potential anti-bacterial activity of doxycycline against various microbes. In vivo data indicated that combining EGF and DOX considerably reduced inflammation time-dependent than single-agent treatment. Furthermore, histological studies corroborated these findings. After topical application of hydrogel, histopathology studies revealed significant collagen synthesis and a fully regenerated epithelial layer and advancement in all three stages (proliferation, remodelling, and maturation), which are required to improve the diabetic wound healing process by any dressing. These findings demonstrated that hydrogel promoted cutaneous wound healing in STZ-induced rats by suppressing inflammation at the wound site. Furthermore, histological studies corroborated these findings. After topical application of hydrogel, histopathology studies revealed significant collagen synthesis, a fully regenerated epithelial layer, and advancement in all three stages (proliferation, remodelling, and maturation), which are required to improve the diabetic wound healing process by any dressing. These findings demonstrated that hydrogel promoted cutaneous wound healing in STZ-induced rats by suppressing inflammation at the wound site.
- Open Access
- 16 September 2022
- Published by Springer Nature in Research Square
Pharmacokinetic and Toxicological Evaluation of Hypophyllanthin Loaded Liposomes
Phyllanthus amarus (P. amarus) is a broad-spectrum medicinal plant and studies have reported anticancer activity of P. amarus to the presence of bioactive lignans such as Phyllanthin and Hypophyllanthin. In vivo studies have shown that hypophyllanthin is a potent inhibitor of cytochrome p450 enzymes (Phase I enzymes) and exhibits cytotoxic effects on K-562 cells. The most common route of drug administration is via oral, and hypophyllanthin, being poorly soluble in water (lipophilic), is highly unsuitable for oral administration. To improve the aqueous solubility and pharmacokinetic profile, hypophyllanthin is formulated as stealth liposomes. The liposomes are developed using film hydration technique and are evaluated for various physicochemical parameters. The synthesized liposomes were found to be in the size range of 128 to 205 nm, PDI was found in the range of 0.2 to 0.3, encapsulation efficiency was found to be in the range 62 to 85, the zeta potential was found in the range of -32 to -40 mV respectively. The pegylated liposome (HPL7) showed superior pharmacokinetics and 86.05% of drug was released over 24 hours. The safety and efficacy of test formulations were established by toxicity and pharmacokinetic studies. The obtained results indicates that, pegylated liposomes are safest and ensures the maximum circulation half life (t1/2), MRT and low elemination constant(Kel) compared to conventional liposomes and pure phyllanthin drug.
- 16 September 2022
- Published by Springer Nature in Research Square
Open AccessPharmacokinetic and Toxicological Evaluation of Hypophyllanthin Loaded Liposomes
Phyllanthus amarus (P. amarus) is a broad-spectrum medicinal plant and studies have reported anticancer activity of P. amarus to the presence of bioactive lignans such as Phyllanthin and Hypophyllanthin. In vivo studies have shown that hypophyllanthin is a potent inhibitor of cytochrome p450 enzymes (Phase I enzymes) and exhibits cytotoxic effects on K-562 cells. The most common route of drug administration is via oral, and hypophyllanthin, being poorly soluble in water (lipophilic), is highly unsuitable for oral administration. To improve the aqueous solubility and pharmacokinetic profile, hypophyllanthin is formulated as stealth liposomes. The liposomes are developed using film hydration technique and are evaluated for various physicochemical parameters. The synthesized liposomes were found to be in the size range of 128 to 205 nm, PDI was found in the range of 0.2 to 0.3, encapsulation efficiency was found to be in the range 62 to 85, the zeta potential was found in the range of -32 to -40 mV respectively. The pegylated liposome (HPL7) showed superior pharmacokinetics and 86.05% of drug was released over 24 hours. The safety and efficacy of test formulations were established by toxicity and pharmacokinetic studies. The obtained results indicates that, pegylated liposomes are safest and ensures the maximum circulation half life (t1/2), MRT and low elemination constant(Kel) compared to conventional liposomes and pure phyllanthin drug.
- Open Access
- 15 September 2022
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 12 (5) , 201-207
A Review on Hot Melt Extrusion Coupled Novel Drug Delivery Systems
The utilization of hot melt extrusion (HME) technology for new applications is increasing in recent years, as evidenced by the many published reports in the last five years. Because of its process automation and low-cost scale-up qualities, which decrease labor expenses and capital investment. HME has emerged as an essential technology for drug delivery applications in pharmaceutical research and manufacture. The novel application of the HME process provides a promising alternate approach in the formulation of novel drug delivery systems. The present review discusses the importance of HME in the development of novel drug delivery systems with the review of relevant case studies. Keywords: hot melt extrusion, novel drug delivery, pharmaceutical research
- 15 September 2022
- Published by Society of Pharmaceutical Tecnocrats in Journal of Drug Delivery and Therapeutics
- Vol. 12 (5) , 201-207
Open AccessA Review on Hot Melt Extrusion Coupled Novel Drug Delivery Systems
The utilization of hot melt extrusion (HME) technology for new applications is increasing in recent years, as evidenced by the many published reports in the last five years. Because of its process automation and low-cost scale-up qualities, which decrease labor expenses and capital investment. HME has emerged as an essential technology for drug delivery applications in pharmaceutical research and manufacture. The novel application of the HME process provides a promising alternate approach in the formulation of novel drug delivery systems. The present review discusses the importance of HME in the development of novel drug delivery systems with the review of relevant case studies. Keywords: hot melt extrusion, novel drug delivery, pharmaceutical research
- 1 June 2014
- Published by American Scientific Publishers in Journal of Bionanoscience
- Vol. 8 (3) , 190-194
Room Temperature Synthesis and Evaluation of Antibacterial Activity of Silver Nanoparticles Using Phyllanthus amarus leaf extract
- 1 June 2014
- Published by American Scientific Publishers in Journal of Bionanoscience
- Vol. 8 (3) , 190-194
Room Temperature Synthesis and Evaluation of Antibacterial Activity of Silver Nanoparticles Using Phyllanthus amarus leaf extract
- 21 February 2014
- Published by Manuscript Technomedia LLP in Pharmacognosy Journal
- Vol. 6 (2) , 45-51
Pharmacokinetic study of phyllanthin and hypophyllanthin after oral administration to rats
- 21 February 2014
- Published by Manuscript Technomedia LLP in Pharmacognosy Journal
- Vol. 6 (2) , 45-51
Pharmacokinetic study of phyllanthin and hypophyllanthin after oral administration to rats
- 6 February 2014
- Published by Elsevier in Asian Pacific Journal of Tropical Disease
- Vol. 4, S71-S76
Investigation of anticancer potential of hypophyllanthin and phyllanthin against breast cancer by in vitro and in vivo methods
- 6 February 2014
- Published by Elsevier in Asian Pacific Journal of Tropical Disease
- Vol. 4, S71-S76
Investigation of anticancer potential of hypophyllanthin and phyllanthin against breast cancer by in vitro and in vivo methods